Hadlima (adalimumab-bwwd) of Samsung Bioepis (a South Korean biopharmaceutical company)/MSD was approved by the U.S. FDA on July 23 as a biosimilar to Humira (generic name: adalimumab) which is a flagship product of AbbVie. It is the third anti-TNF biosimilar of Samsung Bioepis approved in the U.S. and also the fourth biosimilar of the company approved in the U.S.
